BRAF and colorectal carcinoma: Of these prognostic markers, tumor budding is widely used in clinical practice.3 In addition to its use in identifying high-risk stage II CRC patients for the consideration of adjuvant therapy, tumor budding has proven a useful marker in identifying high-risk pT1 tumors after endoscopic or transanal tumor removal.3 In our study, tumor necrosis had prognostic value independent of tumor budding, disease stage, and tumor molecular features including MMR status and BRAF mutation status.